US Patent

US9974826 — Methods comprising desmopressin

Method of Use · Assigned to Ferring BV · Expires 2030-04-13 · 4y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods of using desmopressin to reduce nocturnal voids, increase initial sleep periods, and/or decrease nocturnal urine volume.

USPTO Abstract

The present disclosure is directed to gender, age, and dose effects of desmopressin on reducing nocturnal voids, increasing an initial period of undisturbed sleep, and/or reducing nocturnal urine volume.

Drugs covered by this patent

desmopressin-acetate (DESMOPRESSIN ACETATE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2327`	—	desmopressin-acetate
`U-2326`	—	desmopressin-acetate

Patent Metadata

Patent number: US9974826
Jurisdiction: US
Classification: Method of Use
Expires: 2030-04-13
Drug substance claim: No
Drug product claim: No
Assignee: Ferring BV
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.